TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9773732
Drug: Control (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.1 ml saline)
Study: 8011827
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics administration
Study: 3072016
Drug: Morphine 10
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 10 mg alone
Study: 30511963
Drug: High-dose live
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose live attenuated VZV vaccine
Study: 25574795
Drug: Progesterone for
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone for the Treatment of Traumatic Brain Injury
Study: 17910651
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid withdrawal (decreasing steroid doses stopping at day 7 post-transplant)
Study: 17910651
Drug: Early steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early steroid withdrawal
Study: 17910651
Drug: Steroid-based control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-based control group (CsA, AZT)
Study: 17910651
Drug: Steroid-based control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-based control group
Study: 9513957
Drug: Paravertebral blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral blockade (steroid + local anaesthetic)
Study: 9513957
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (spine-decompressing position, traction, therapeutic exercises)
Study: 29773818
Drug: Anti-malarial compounds
Normalized name: malarial plasmodium group immunoserum rabbit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-malarial compounds in EIA
Study: 29773818
Drug: pIC50 for
Approvals — FDA: no, EMA: no, PMDA: no
Description: pIC50 for 11 different compounds in EIA
Study: 21211323
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) administered for 1 - 3 cycles before radical hysterectomy and lymphadenectomy.
Study: 21211323
Drug: Director operation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Director operation (DOR) without prior chemotherapy, radical hysterectomy performed directly after diagnosis.
Study: 16009171
Drug: Raloxifene 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 180 mg/day orally for three cycles of 28 days
Study: 16009171
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (3 tablets/day orally)
Study: 2878597
Drug: Bevantolol 400
Normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevantolol 400 mg
Study: 30922101
Drug: Single ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ketamine infusion
Study: 31759333
Drug: Repeated ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated ketamine infusions (six infusions thrice-weekly over 2 weeks)
Study: 31759333
Drug: Maintenance infusions
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance infusions (four further infusions once-weekly)
Study: 30175606
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (third administration)
Study: 21182551
Drug: Active gum
Normalized name: STANNOUS FLUORIDE 1.1 mg in 1 g DENTAL PASTE [parodontax Active Gum Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active gum (2 mg or 4 mg)
Study: 21182551
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (2 mg or 4 mg)
Study: 17446413
Drug: Intralipid (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (0.8 ml x m(‐2) x min(‐1)) and heparin (1,000 U/h)
Study: 17446413
Drug: Saline (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.8 ml x m(‐2) x min(‐1)) and heparin (1,000 U/h)
Study: 8130921
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine patches (delivering 15 mg over 16 hours) with low-intensity support
Study: 31650529
Drug: Active iliopsoas
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active iliopsoas plane block (5 mL lidocaine 18 mg/mL with epinephrine)
Study: 29313751
Drug: 2-dose-ZW (28
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose-ZW (28 g)
Study: 29313751
Drug: 1-dose-ZW (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose-ZW (14 g)
Study: 28088231
Drug: Gabapentin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (maximum of 1800 mg/day for 5 weeks)
Study: 11243947
Drug: Salmeterol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol (50 microg, twice daily)
Study: 16893984
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg PS vaccinating dose
Study: 9009369
Drug: 0.04% mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% mitomycin C eye drops, four times daily for two weeks or longer after surgery
Study: 25189175
Drug: Hypertonic sodium
Normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic sodium lactate solution (HSL) - 5 ml/kg/BW in 15 minutes followed by 1 ml/kg/BW/h for 12 hours
Study: 25189175
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate (RL) - 20 ml/kg/BW in 15 minutes followed by decreasing doses of 10, 7, 5, and 3 ml/kg BW/h for 12 hours
Study: 25189175
Drug: Hypertonic sodium
Normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic sodium lactate solution (HSL)
Study: 16359401
Drug: Vi polysaccharide
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi polysaccharide (PS) vaccine
Study: 11953977
Drug: Pulse cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse cyclophosphamide, pulse methylprednisolone, or the combination of both
Study: 11953977
Drug: Additional immunosuppressive
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional immunosuppressive therapy
Study: 7824101
Drug: L/R HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/R HF ratios
Study: 19621834
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy with exposure and response prevention
Study: 19621834
Drug: Augmentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation of SSRI with atypical antipsychotic
Study: 3981411
Drug: Repeat-action combination
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat-action combination tablet containing 6 mg of dexbrompheniramine maleate with 120 mg of pseudoephedrine sulfate every 12 h for 7 d
Study: 3981411
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of conventional 2-mg dexbrompheniramine maleate tablets every 4 h and 120-mg pseudoephedrine sulfate repeat-action tablets every 12 h, each for 7 d
Study: 27589059
Drug: MD1003 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD1003 (100 mg biotin)
Study: 22348492
Drug: 5mg/kg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg/kg oral erythromycin every 6 hours for 14 days (n=19)
Study: 19136327
Drug: Psychoeducational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychoeducational intervention to reduce severity of oral mucositis and oral pain
Study: 12363116
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy plus paroxetine (40 mg/day)
Study: 12363116
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy plus placebo
Study: 7721239
Drug: Granular (G)
Normalized name: Saxifraga granulata whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granular (G) type duodenitis
Study: 2481775
Drug: Felodipine-ER 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-ER 10 mg
Study: 2481775
Drug: Felodipine-ER 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-ER 20 mg
Study: 1234484
Drug: Trazodone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (single oral dose)
Study: 23193217
Drug: Closed-loop basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop basal insulin delivery
Study: 21632228
Drug: Glycopyrrolate 0.4
Normalized name: glycopyrrolate 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.4 mg
Study: 17566124
Drug: Levetiracetam (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (maximum dose 30 mg/kg/day)
Study: 12116023
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg three times a day
Study: 9537221
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg azimilide orally each day
Study: 9537221
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg azimilide orally each day
Study: 2675895
Drug: Azathioprine (AZA;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (AZA; 2 mg/kg per day) in combination with CyA (group AZA+)
Study: 593193
Drug: Triphasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic preparation with a sequence of 6/5/10
Study: 593193
Drug: Triphasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic preparation with a reduced content of total dose of oestrogen per cycle
Study: 25870057
Drug: BMS‐663068 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐663068 at 600 mg BID
Study: 25870057
Drug: BMS‐663068 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐663068 at 600 mg BID plus RTV at 100 mg QD
Study: 25870057
Drug: ATV/r (ATV
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/r (ATV at 300 mg QD plus RTV at 100 mg QD)
Study: 25870057
Drug: BMS‐663068 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐663068 at 600 mg BID plus ATV at 300 mg QD plus RTV at 100 mg QD
Study: 10179922
Drug: NSAID therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID therapy (not specified)
Study: 7917153
Drug: Human Ser-Tyr28
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human Ser-Tyr28 ANH (0.6 pmol/kg/min) infusion during low-salt diet (LS+ANH)
Study: 7917153
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion during low-salt diet (LS)
Study: 7917153
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion during high-salt diet (HS)
Study: 2576363
Drug: picumast dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: picumast dihydrochloride 1 mg
Study: 31789554
Drug: Alcoholic beverage
Normalized name: Alcoholic beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcoholic beverage (target BrAC = .08 g%)
Study: 30496426
Drug: Good value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Good value estimation methodology (total cholesterol of 170 mg/dl and HDL‐cholesterol of 50 mg/dl)
Study: 27013221
Drug: Acceptance Commitment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance Commitment Therapy (ACT) intervention; 6 sessions
Study: 26606003
Drug: High-volume injectate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume injectate (8 mL)
Study: 26606003
Drug: Low-volume injectate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume injectate (3 mL)
Study: 23368828
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg/kg of body mass/day)
Study: 19889067
Drug: EAC (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAC (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and clarithromycin 500 mg b.d.)
Study: 19889067
Drug: EAL (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAL (esomeprazole 20 mg b.d., amoxycillin 1 g b.d., and levofloxacin 500 mg daily)
Study: 17230483
Drug: Preoperative medication
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative medication responsiveness
Study: 14764786
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment with dosages of 1 mg/m².d and 2 mg/m².d (approximately 0.035 and 0.070 mg/kg.d, respectively) for 1 year
Study: 8997462
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial gels containing 4 times minimally inhibitory in vitro concentrations
Study: 8997462
Drug: Topical antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antimicrobial gels containing 8 times minimally inhibitory in vitro concentrations
Study: 8203854
Drug: Aztreonam (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (6 g/day [2 g intravenously every 8 h] for 10 days)
Study: 8203854
Drug: Chloramphenicol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol (50 mg/kg of body weight per day [intravenously or orally] for 14 days)
Study: 3555596
Drug: PUVA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA with oral 8‐methoxypsoralen (8‐MOP)
Study: 3555596
Drug: UVB with
Normalized name: ZINC OXIDE 20 g in 100 g TOPICAL LOTION [restorsea Rejuvenating Day SPF 30 Broad Spectrum UVA UVB with Vibransea Complex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB with oral placebo
Study: 3555596
Drug: Control low‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control low‐dose UVA with oral placebo
Study: 31173464
Drug: High-intensity focused
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity focused ultrasound treatment
Study: 16172545
Drug: Desipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (50 mg once daily)
Study: 16172545
Drug: Escitalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10 mg once daily)
Study: 345632
Drug: Meglumine iodamide
Normalized name: meglumine iodamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine iodamide (0.8 cc/kg to a maximum of 55 cc)
Study: 345632
Drug: Renografin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renografin 60 (52% meglumine diatrizoate and 8% sodium diatrizoate) (0.8 cc/kg to a maximum of 55 cc)
Study: 24322420
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of ATP injected before PVI in AF patients
Study: 24322420
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of ATP injected in AVRT patients
Study: 21960668
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg single dose)
Study: 17445634
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin (125 mg) every 8 hours (maximum of 21 doses)
Study: 19759966
Drug: Energy conservation
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy conservation training (1 to 2 hours of individual training followed by weekly telephone monitoring for 3 weeks)
Study: 10555027
Drug: Sulfasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine (SSZ) 2000 mg/day
Study: 8707971
Drug: Active prescale
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active prescale gel
Study: 8707971
Drug: Active prescale
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active prescale gel (extended exposure)
Study: 1762068
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg of morphine
Study: 1762068
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg of morphine
Study: 1762068
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of morphine
Study: 1762068
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of morphine
Study: 1762068
Drug: Lowest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest dose of morphine (not specified)
Study: 1762068
Drug: Intermediate doses
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate doses of morphine (not specified)
Study: 1762068
Drug: Highest dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest dose of morphine (30 mg)
Study: 6347229
Drug: Metoprolol SA
Normalized name: metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol SA 200 mg once daily
Study: 31389784
Drug: methyl‐5‐aminolevulinate 16%
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyl‐5‐aminolevulinate 16% cream-Photodynamic therapy (PDT)
Study: 31389784
Drug: imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: imiquimod 5% cream
Study: 27352310
Drug: Baicalein 200
Normalized name: Baicalein
DrugBank: Baicalein (DB16101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baicalein 200 mg once daily on days 1 and 10, twice daily on days 3-9
Study: 27352310
Drug: Baicalein 400
Normalized name: Baicalein
DrugBank: Baicalein (DB16101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baicalein 400 mg once daily on days 1 and 10, twice daily on days 3-9
Study: 27352310
Drug: Baicalein 800
Normalized name: Baicalein
DrugBank: Baicalein (DB16101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baicalein 800 mg once daily on days 1 and 10, twice daily on days 3-9
Study: 12457671
Drug: Fentanyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (5 microg bolus doses via PCA after IV loading dose of 0.7 microg/kg)
Study: 12457671
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (balanced salt solution without analgesic via PCA)
Study: 10542999
Drug: C1-inhibitor administration
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor administration
Study: 8949757
Drug: twice‐daily neutron
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice‐daily neutron therapy for advanced head and neck cancer
Study: 8949757
Drug: neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: neutron therapy for advanced salivary gland tumours
Study: 8949757
Drug: neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: neutron therapy for locally advanced breast cancer
Study: 8949757
Drug: neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: neutron therapy for macroscopic residual soft tissue sarcomas
Study: 8949757
Drug: neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: neutron therapy for macroscopic residual uterine sarcoma
Study: 8949757
Drug: neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: neutron therapy for advanced squamous carcinoma of the maxillary antrum
Study: 8949757
Drug: neutron therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: neutron therapy for advanced osteosarcomas and chondrosarcomas
Study: 1681558
Drug: Loprazolam 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loprazolam 2 mg
Study: 28261955
Drug: Beloranib 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beloranib 1.8 mg subcutaneously twice weekly for 4 weeks
Study: 28261955
Drug: Beloranib 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beloranib 1.8 mg (after 4-week open-label extension)
Study: 28261955
Drug: Beloranib treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beloranib treatment
Study: 20932798
Drug: 6.4% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% maltodextrin solution [Mal]
Study: 20932798
Drug: 7.1% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.1% glucose solution [Glu]
Study: 31441852
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (continuous infusion with 0.01 mg/kg/h and a bolus dose with 0.03 mg/kg)
Study: 31441852
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (a bolus dose with 0.03 mg/kg)
Study: 31441852
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (PCA administered as a time‐scheduled decremental continuous infusion based on lean body mass)
Study: 21912321
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (control)
Study: 16962938
Drug: High phenolic
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High phenolic content virgin olive oil (25 ml/day for 3 weeks)
Study: 11193166
Drug: Talsaclidine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talsaclidine (selective muscarinic M1 agonist), administered for 4 weeks
Study: 11193166
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group), administered for 4 weeks
Study: 9076645
Drug: Estrogen implant
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen implant
Study: 3790956
Drug: Cefuroxime (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1.5 g IV/8 h for 2 days)
Study: 3790956
Drug: Metronidazole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (1 g IV on induction and 12 h postoperatively)
Study: 23011911
Drug: Chemoradiation (CRT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation (CRT) with concurrent 5-fluorouracil/mitomycin C